Citigroup Lowers Agilent Technologies (NYSE:A) Price Target to $130.00

Agilent Technologies (NYSE:A – Get Rating) had its price target decreased by equities researchers at Citigroup from $150.00 to $130.00 in a research report issued on Wednesday, The Fly reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Citigroup’s price target indicates a potential upside of 8.80% from the stock’s current price.

A number of other equities research analysts also recently issued reports on the stock. Credit Suisse Group upped their price objective on shares of Agilent Technologies from $165.00 to $170.00 and gave the stock an “outperform” rating in a research report on Wednesday, March 1st. StockNews.com assumed coverage on shares of Agilent Technologies in a research note on Thursday, May 18th. They set a “buy” rating on the stock. Barclays lowered their target price on shares of Agilent Technologies from $140.00 to $135.00 and set an “equal weight” rating on the stock in a research note on Wednesday. Finally, Robert W. Baird raised their price objective on shares of Agilent Technologies from $170.00 to $174.00 and gave the company an “outperform” rating in a research report on Wednesday, March 1st. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $151.35.

Agilent Technologies Price Performance

Shares of NYSE A opened at $119.49 on Wednesday. The company has a fifty day moving average price of $133.52 and a 200 day moving average price of $143.94. Agilent Technologies has a 1-year low of $112.52 and a 1-year high of $160.26. The company has a current ratio of 2.11, a quick ratio of 1.53 and a debt-to-equity ratio of 0.49. The firm has a market cap of $35.33 billion, a PE ratio of 26.32, a PEG ratio of 1.89 and a beta of 1.03.

Agilent Technologies (NYSE:A – Get Rating) last announced its earnings results on Tuesday, May 23rd. The medical research company reported $1.27 EPS for the quarter, topping the consensus estimate of $1.26 by $0.01. Agilent Technologies had a net margin of 19.19% and a return on equity of 30.74%. The company had revenue of $1.72 billion for the quarter, compared to analysts’ expectations of $1.67 billion. During the same period last year, the firm earned $1.13 earnings per share. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. Research analysts predict that Agilent Technologies will post 5.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Agilent Technologies

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Financial Gravity Asset Management Inc. purchased a new stake in Agilent Technologies during the 1st quarter worth about $2,108,000. Money Concepts Capital Corp bought a new stake in shares of Agilent Technologies in the 4th quarter valued at approximately $26,000. Delta Asset Management LLC TN bought a new position in Agilent Technologies during the 4th quarter worth $26,000. Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. acquired a new position in Agilent Technologies during the 4th quarter worth $27,000. Finally, Newbridge Financial Services Group Inc. lifted its holdings in shares of Agilent Technologies by 217.6% in the fourth quarter. Newbridge Financial Services Group Inc. now owns 216 shares of the medical research company’s stock valued at $32,000 after buying an additional 148 shares during the period. Hedge funds and other institutional investors own 85.51% of the company’s stock.

Agilent Technologies Company Profile

(Get Rating)

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.